Analytical Standards

Rixvia manufactures research-grade peptide therapeutics under strict analytical standards. Every production lot undergoes independent third-party testing before release, and the resulting Certificate of Analysis is published and indexed by lot number.

Testing Methodology

Purity is determined via High-Performance Liquid Chromatography (HPLC) with UV detection. Identity confirmation is performed via Liquid Chromatography coupled with Tandem Mass Spectrometry (LC-MS/MS). Net peptide content is quantified per vial and reported against the labeled dose.

Third-Party Analysis

All analytical work is performed by accredited independent laboratories. Rixvia does not conduct in-house purity testing. This separation ensures objectivity and eliminates conflicts of interest in quality reporting.

Storage & Handling

All lyophilized peptides should be stored at 2–8°C prior to reconstitution. Once reconstituted, peptide solutions should be refrigerated and used within the timeframe specified on the product label. Protect from light and repeated freeze-thaw cycles.

Release Criteria

No lot is released for sale until the Certificate of Analysis confirms purity at or above 98%, identity is confirmed via mass spectrometry, and net peptide content meets or exceeds the labeled dose. Lots that fail any criterion are rejected.